ATE299885T1 - Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung - Google Patents

Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung

Info

Publication number
ATE299885T1
ATE299885T1 AT00902934T AT00902934T ATE299885T1 AT E299885 T1 ATE299885 T1 AT E299885T1 AT 00902934 T AT00902934 T AT 00902934T AT 00902934 T AT00902934 T AT 00902934T AT E299885 T1 ATE299885 T1 AT E299885T1
Authority
AT
Austria
Prior art keywords
production
short chain
chain polynucleotides
same
polynucleotides
Prior art date
Application number
AT00902934T
Other languages
English (en)
Inventor
Shinji Matsuyama
Kouichi Ishiyama
Junzo Seki
Tadaaki Ohgi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ATE299885T1 publication Critical patent/ATE299885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00902934T 1999-02-15 2000-02-14 Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung ATE299885T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3596399 1999-02-15
PCT/JP2000/000778 WO2000047601A1 (en) 1999-02-15 2000-02-14 Shortened-chain polynucleotides and process for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE299885T1 true ATE299885T1 (de) 2005-08-15

Family

ID=12456623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902934T ATE299885T1 (de) 1999-02-15 2000-02-14 Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung

Country Status (14)

Country Link
US (2) US6780429B1 (de)
EP (1) EP1153931B1 (de)
KR (1) KR100455814B1 (de)
CN (1) CN1194002C (de)
AT (1) ATE299885T1 (de)
AU (1) AU2460900A (de)
BR (1) BR0008227A (de)
CA (1) CA2359674A1 (de)
DE (1) DE60021354T2 (de)
ID (1) ID29546A (de)
NO (1) NO20013941D0 (de)
RU (1) RU2238279C2 (de)
WO (1) WO2000047601A1 (de)
ZA (1) ZA200106701B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response
EP1582584A4 (de) * 2002-12-26 2006-05-31 Nippon Shinyaku Co Ltd HERSTELLUNGSVERFAHREN FÜR PNPase
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
KR20100045508A (ko) * 2007-08-13 2010-05-03 콜리 파마슈티칼 게엠베하 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
EP2116602A1 (de) 2008-05-07 2009-11-11 Institut Gustave Roussy Kombinationsprodukte zur Behandlung von Krebs
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
EP2542670A2 (de) 2010-03-05 2013-01-09 President and Fellows of Harvard College Zusammensetzungen aus induzierten dentritischen zellen und ihre verwendung
WO2012088272A1 (en) 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
EP2858722B8 (de) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Zusammensetzungen und verfahren zur krebsimmuntherapie
JP6446269B2 (ja) * 2012-12-06 2018-12-26 協和発酵バイオ株式会社 アジュバント用二重鎖リボ核酸
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
WO2025229953A1 (ja) * 2024-04-30 2025-11-06 住友化学株式会社 オリゴヌクレオチドの製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3666646A (en) 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
US5298614A (en) * 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
GB2207138B (en) * 1987-07-03 1992-02-05 Nippon Shinyaku Co Ltd Preparation of nucleic acid derivatives.
KR100283601B1 (ko) * 1993-02-19 2001-03-02 아만 히데아키 글리세롤 유도체, 디바이스 및 의약 조성물
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments

Also Published As

Publication number Publication date
US20040235044A1 (en) 2004-11-25
NO20013941L (no) 2001-08-14
CN1194002C (zh) 2005-03-23
NO20013941D0 (no) 2001-08-14
KR20020013500A (ko) 2002-02-20
CN1340055A (zh) 2002-03-13
EP1153931B1 (de) 2005-07-20
AU2460900A (en) 2000-08-29
EP1153931A4 (de) 2002-07-17
CA2359674A1 (en) 2000-08-17
ZA200106701B (en) 2002-11-14
ID29546A (id) 2001-09-06
WO2000047601A1 (en) 2000-08-17
KR100455814B1 (ko) 2004-11-06
US6780429B1 (en) 2004-08-24
BR0008227A (pt) 2001-10-30
RU2238279C2 (ru) 2004-10-20
DE60021354D1 (de) 2005-08-25
US7223857B2 (en) 2007-05-29
DE60021354T2 (de) 2006-04-27
EP1153931A1 (de) 2001-11-14

Similar Documents

Publication Publication Date Title
ATE299885T1 (de) Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
DE69813523D1 (de) Polyalkoxysiloxanverbindungen,verfahren zur herstellung und diese verbindungen enthaltende beschichtungszusammensetzungen
DE59906105D1 (de) Verfahren zur kontinuierlichen herstellung von 1,3-dioxolan-2-onen
DE68904986D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichlorethan.
DE69832209D1 (de) Verfahren zur Herstellung von 3,3-Dimethylbutyraldehyd durch Oxidation von 3,3-Dimethylbutanol
DE68907320D1 (de) Verfahren zur herstellung von modifizierten polypropylen-zusammensetzungen.
DE69909003D1 (de) Verfahren zur Herstellung von Polyamiden
DE69823662D1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE68916035D1 (de) Verfahren zur selektiven herstellung von 2,6-dialkylnaphthalenen.
DE3768426D1 (de) Verfahren zur herstellung von 4,4'-biphenyldicarbonsaeure.
DE59905197D1 (de) Verfahren zur herstellung von hexandiol-1,6
DE50006245D1 (de) Verfahren zur herstellung von (1,1':4',1'')-terphenylvebindungen
DE59705787D1 (de) Verfahren zur herstellung von n,n'-dialkylperylen-3,4,9,10-tetracarbonsäurediimiden
ATE366251T1 (de) Verfahren zur herstellung von 1,3- disubstituierten-4-oxocyclischen harnstoffen
DE59804673D1 (de) Verfahren zur herstellung von vinylphosphonsäure-verbindungen
ATE125700T1 (de) Ibuprofen- und s-(+)-ibuprofen zubereitungen und verfahren zu ihrer herstellung.
DE59902581D1 (de) Verfahren zur herstellung von vinylphosphonsäure-verbindungen
DE59611076D1 (de) Verfahren zur herstellung von 5,6-dihydro-1,3-oxazinen
DE3874496D1 (de) Verfahren zur herstellung von 4,4'-dibrombiphenyl.
ATE275563T1 (de) Verfahren zur herstellung von 1,3- disubstituierten-4-oxocyclischen harnstoffen
DE3860061D1 (de) Verfahren zur herstellung von 4,4'-dinitrostilben-2,2'-disulfonsaeure.
DE3781095D1 (de) Calciumhypochloritzusammensetzungen und verfahren zu ihrer herstellung.
DE59801815D1 (de) Verfahren zur herstellung von 1,2-dichlorethan durch oxichlorierung
DE69815393D1 (de) Verfahren zur kontinuierlichen herstellung von kaugummi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties